Julia Kroth1, Dumitru Ciolac2, Vinzenz Fleischer1, Nabin Koirala1, Julia Krämer3, Muthuraman Muthuraman1, Felix Luessi1, Stefan Bittner1, Gabriel Gonzalez-Escamilla1, Frauke Zipp1, Sven G Meuth3, Sergiu Groppa1. 1. Department of Neurology, Focus Program Translational Neuroscience (FTN), Research Center for Immunology (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. 2. Department of Neurology, Focus Program Translational Neuroscience (FTN), Research Center for Immunology (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany/Department of Neurology, Institute of Emergency Medicine, Laboratory of Neurobiology and Medical Genetics, Nicolae Testemiţanu State University of Medicine and Pharmacy, Chisinau, Moldova. 3. Department of Neurology, University of Munster, Munster, Germany.
Abstract
BACKGROUND: Currently, no unequivocal predictors of disease evolution exist in patients with multiple sclerosis (MS). Cortical atrophy measurements are, however, closely associated with cumulative disability. OBJECTIVE: Here, we aim to forecast longitudinal magnetic resonance imaging (MRI)-driven cortical atrophy and clinical disability from cerebrospinal fluid (CSF) markers. METHODS: We analyzed CSF fractions of albumin and immunoglobulins (Ig) A, G, and M and their CSF to serum quotients. RESULTS: Widespread atrophy was highly associated with increased baseline CSF concentrations and quotients of albumin and IgA. Patients with increased CSFIgA and CSFIgM showed higher functional disability at follow-up. CONCLUSION: CSF markers of blood-brain barrier integrity and specific immune response forecast emerging gray matter pathology and disease progression in MS.
BACKGROUND: Currently, no unequivocal predictors of disease evolution exist in patients with multiple sclerosis (MS). Cortical atrophy measurements are, however, closely associated with cumulative disability. OBJECTIVE: Here, we aim to forecast longitudinal magnetic resonance imaging (MRI)-driven cortical atrophy and clinical disability from cerebrospinal fluid (CSF) markers. METHODS: We analyzed CSF fractions of albumin and immunoglobulins (Ig) A, G, and M and their CSF to serum quotients. RESULTS: Widespread atrophy was highly associated with increased baseline CSF concentrations and quotients of albumin and IgA. Patients with increased CSFIgA and CSFIgM showed higher functional disability at follow-up. CONCLUSION: CSF markers of blood-brain barrier integrity and specific immune response forecast emerging gray matter pathology and disease progression in MS.
Authors: Anne-Katrin Pröbstel; Xiaoyuan Zhou; Ryan Baumann; Sven Wischnewski; Michael Kutza; Olga L Rojas; Katrin Sellrie; Antje Bischof; Kicheol Kim; Akshaya Ramesh; Ravi Dandekar; Ariele L Greenfield; Ryan D Schubert; Jordan E Bisanz; Stephanie Vistnes; Khashayar Khaleghi; James Landefeld; Gina Kirkish; Friederike Liesche-Starnecker; Valeria Ramaglia; Sneha Singh; Edwina B Tran; Patrick Barba; Kelsey Zorn; Johanna Oechtering; Karin Forsberg; Lawrence R Shiow; Roland G Henry; Jennifer Graves; Bruce A C Cree; Stephen L Hauser; Jens Kuhle; Jeffrey M Gelfand; Peter M Andersen; Jürgen Schlegel; Peter J Turnbaugh; Peter H Seeberger; Jennifer L Gommerman; Michael R Wilson; Lucas Schirmer; Sergio E Baranzini Journal: Sci Immunol Date: 2020-11-20
Authors: Vinzenz Fleischer; Gabriel Gonzalez-Escamilla; Dumitru Ciolac; Philipp Albrecht; Patrick Küry; Joel Gruchot; Michael Dietrich; Christina Hecker; Thomas Müntefering; Stefanie Bock; Mohammadsaleh Oshaghi; Angela Radetz; Manuela Cerina; Julia Krämer; Lydia Wachsmuth; Cornelius Faber; Hans Lassmann; Tobias Ruck; Sven G Meuth; Muthuraman Muthuraman; Sergiu Groppa Journal: Proc Natl Acad Sci U S A Date: 2021-09-07 Impact factor: 11.205
Authors: Dumitru Ciolac; Felix Luessi; Gabriel Gonzalez-Escamilla; Nabin Koirala; Christian Riedel; Vinzenz Fleischer; Stefan Bittner; Julia Krämer; Sven G Meuth; Muthuraman Muthuraman; Sergiu Groppa Journal: Front Immunol Date: 2019-07-30 Impact factor: 7.561
Authors: Amelie Bos; Esil Aleyd; Lydia P E van der Steen; P J Winter; Niels Heemskerk; Stephan M Pouw; Louis Boon; Rene J P Musters; Jantine E Bakema; Cassian Sitaru; Michel Cogné; Marjolein van Egmond Journal: Front Immunol Date: 2022-03-15 Impact factor: 7.561
Authors: Amélie V Bos; Melissa M J van Gool; Annelot C Breedveld; Richard van der Mast; Casper Marsman; Gerd Bouma; Mark A van de Wiel; S Marieke van Ham; Reina E Mebius; Marjolein van Egmond Journal: Int J Mol Sci Date: 2022-09-22 Impact factor: 6.208
Authors: Vanesa Cunill; Margarita Massot; Antonio Clemente; Carmen Calles; Valero Andreu; Vanessa Núñez; Antonio López-Gómez; Rosa María Díaz; María de Los Reyes Jiménez; Jaime Pons; Cristòfol Vives-Bauzà; Joana Maria Ferrer Journal: Front Immunol Date: 2018-05-29 Impact factor: 7.561